Experimental assessment of computationally nominated small molecules targeting the YAP–TEAD interface in Hippo pathway-altered mesothelioma cell models - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of Computationally Identified Small Molecules Targeting the YAP–TEAD Interaction in Mesothelioma Cell Models with Altered Hippo Pathway Activity

  • By

  • Glen J. Weiss

  • Joseph C. Loftus

  • David W. Mallery

  • Nhan L. Tran

  • September 14, 2026

Share

  • 1

    The study evaluated small molecules targeting the YAP–TEAD interaction in mesothelioma cell models with altered Hippo pathway activity.

  • 2

    Computational screening of approximately 917,000 compounds identified candidates for experimental assessment of their antiproliferative effects.

  • 3

    The validated TEAD inhibitor K-975 showed dose-dependent antiproliferative effects in some mesothelioma cell lines, while cisplatin decreased viability in all.

  • 4

    None of the computationally nominated compounds demonstrated measurable antiproliferative activity at the tested concentrations.

  • 5

    The findings highlight a limited concordance between computational nominations and actual cell-based activity in targeting the YAP–TEAD interface.

Original Source(s)

Experimental assessment of computationally nominated small molecules targeting the YAP–TEAD interface in Hippo pathway-altered mesothelioma cell models

  • by Glen J. Weiss, Joseph C. Loftus, David W. Mallery, Nhan L. Tran

  • September 14, 2026

Related Content

Cost-Effectiveness of Electronic Patient-Reported Outcome Measure Interventions in Cancer: Systematic Review and Parameter Extraction for Economic Modeling

Case Report: Treatment of an unresectable mucoepidermoid carcinoma with osimertinib

Correction: Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rare WDR43::ALK structural deletion